NCT03751761 2024-02-28GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyAsan Medical CenterPhase 1/2 Completed58 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled